Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Plus: The story behind the award-winning science that led to Ozempic, the next astronaut launch and why homework is good for ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Three doctors have expressed concerns to Newsweek about weight loss drugs for children, with research suggesting an initial reluctance to prescribe them.

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...

Kourtney Kardashian’s supplement brand, Lemme has launched a natural weight loss aid. GLP-1 Daily is named for the active ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic—so ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...